AstraZeneca’s rare disease arm Alexion agreed to resolve all patent disputes with Chugai Pharmaceutical regarding the prescription drug Ultomiris (ravulizumab) by signing a settlement agreement that will involve a one-time payment of $775 million.
https://www.pharmalive.com/wp-content/uploads/2021/10/AstraZeneca-Pays-560K-to-Settle-Race-Gender-Discrimination-Allegations-BioSpace-10-5-21.jpeg350625Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-03-17 11:51:442022-03-17 11:52:17Alexion Settles Patent Infringement Lawsuits Against Ultomiris for $775 Million